Aims/hypothesis. Type I (insulin-dependent) diabetes results mainly from T-cell-mediated autoimmune destruction of pancreatic beta cells.
Cytotoxic T lymphocytes destroy target cells via a perforin-based or Fas-based mechanism. Our previous study indicated that
the Fas-Fas ligand (FasL) pathway is required for the development of autoimmune diabetes in the NOD mouse. We now investigated
whether or not the Fas-FasL system is involved in the beta-cell destruction in human Type I diabetes.
Methods. We immunohistochemically analysed pancreas biopsy specimens of 13 recent-onset patients.
Results. Pancreatic islets were identified but showed various degrees of reduction in beta-cell volume in all patients. Out of 13
patients 6 had insulitis. In these 6 patients Fas was expressed in both the islets and infiltrating cells but not in either
cell type in the 7 other patients without insulitis. Double immunostaining showed that Fas was positive in 92.2 to 97.7 %
of beta cells but only in 17.6 to 46.7 % of alpha cells in Fas-positive, insulin-remaining islets. We found FasL was expressed
exclusively in islet-infiltrating cells in patients with insulitis. Double immunostaining revealed that the most prevalent
phenotype of FasL-positive cells was CD8, which was followed by macrophages and CD4.
Conclusion/interpretation. The interaction between Fas on beta cells and FasL on infiltrating cells might trigger selective apoptotic beta-cell death
in inflamed islets, leading to immune-mediated Type I diabetes. [Diabetologia (1999) 42: 1332–1340]
Keywords Type I diabetes - Fas - Fas ligand - insulitis - human pancreas - apoptosis.
Received: 3 March 1999 and in final revised form: 9 July 1999